There are currently no proven treatments to reverse Alzheimer’s but researchers are actively looking into treatments and therapies that could decrease the pace of disease progression and cognitive decline. An experimental drug may be on the path to achieve that goal after it was able to slow cognitive decline by 38% over two years in people with early-stage Alzheimer’s. The development came to light after new clinical trial findings were announced by pharmaceutical company Biogen.Experimental Alzheimer's Drug Slows Cognitive DeclineThe experimental drug that targets a protein linked to Alzheimer's disease is called diranersen (BIIB080). It is equipped to reduce levels of tau, a protein that accumulates abnormally in the brains of people with Alzheimer's disease and causes damage to nerve cells.Results from the Phase 2 CELIA trial, presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference, showed that patients receiving the lowest dose of diranersen experienced more cognitive decline at two years than was reported at the 18-month assessment.The 60 mg dose, administered through an injection into the fluid surrounding the spinal cord twice a year, slowed cognitive decline by 38% on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale at 96 weeks. This was an improvement from the 26% slowing that was observed at 76 weeks.The two-year results corresponded to a 1.09-point difference on the CDR-SB scale compared to the control group. The scale measures changes in memory, thinking abilities and the ability to do everyday activities.Also read: 'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's PatientsHow Does The Investigational Alzheimer's Drug Work?Tau is a protein that normally helps maintain the structure and stability of nerve cells. But, in Alzheimer's disease, tau can become abnormal, clump together and form structures known as neurofibrillary tangles inside brain cells.They interfere with the normal functioning of nerve cells and can lead to progressive brain damage, memory loss and cognitive decline, symptoms usually seen in Alzheimer’s patients.Diranersen belongs to a class of medicines that work by targeting genetic messages involved in producing proteins. In this case, diranersen targets the messenger RNA (mRNA) produced by the MAPT gene, which carries instructions for making tau protein. By targeting this genetic message, the drug aims to reduce the production of tau at source.Recently approved Alzheimer's treatments like lecanemab and donanemab target amyloid-beta plaques, another abnormal protein accumulation associated with the disease. They work by helping the body clear amyloid deposits from the brain and have demonstrated modest slowing of cognitive decline in people with early Alzheimer's.Diranersen works differently by targeting tau production rather than amyloid accumulation.Also read: Older Adults Receiving High-Dose Flu Shots Show Lower Alzheimer's Risk: Study Side Effects Of Diranersen Biogen reported that diranersen was well tolerated over the two-year observation period as no new safety concerns came up. Side effects mostly included headaches and back pain, which could have been due to lumbar puncture procedure used to administer the drug. A small number of participants also experienced confusion.Unlike some existing Alzheimer's treatments, the trial did not report cases of amyloid-related brain swelling.Diranersen is still undergoing clinical development and is not approved by the US Food and Drug Administration (FDA) or other regulatory authorities.